Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment




Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.

Leave a Reply

Your email address will not be published. Required fields are marked *